Where is Amgen headquarters in the US?
Amgen, one of the world's largest independent biotechnology companies, maintains its global corporate headquarters in Thousand Oaks, California, United States. Situated in the Conejo Valley region of Ventura County, this expansive campus serves as the central nerve center for the company's worldwide research, development, clinical manufacturing, and executive operations. From this primary California headquarters, Amgen coordinates its international network of biopharmaceutical innovation hubs, advanced manufacturing plants, and widespread commercial offices that deliver essential medications for cardiovascular disease, oncology, bone health, and inflammatory conditions to millions of patients globally. The Thousand Oaks location houses the core scientific research laboratories and executive leadership teams driving the company’s ongoing breakthroughs in human therapeutics and genetic engineering technologies.
Related FAQs
Amgen Inc., one of the world's pioneering independent biotechnology corporations, officially completed its initial public offering on June 17, 1983.
Amgen operates uniquely as a pioneer that bridges both categories, functioning as one of the world's largest independent biotechnology enterprises while possessing the massive scale, global commercial infrastructure, and extensive manufacturing capac...
Amgen is a global biotechnology pioneer widely known for developing and commercializing groundbreaking biologic therapies that address serious, life-threatening illnesses across multiple therapeutic areas.
Vice presidents managing commercial banking portfolios, risk assessment divisions, retail financial operations, or wealth management at Bank of Montreal (BMO) earn professional compensation packages reflecting major Canadian and North American bankin...
Legendary Bollywood actor Amitabh Bachchan maintained a long-standing, high-profile professional relationship with Kalyan Jewellers as their primary global brand ambassador.
Amgen stock maintains a promising future outlook driven by its robust biotechnology pipeline, innovative biologic therapeutics, and expanding portfolio in oncology, cardiovascular disease, and inflammation.
Amgen Inc. (AMGN) is a premier biotechnology heavyweight offering a compelling mix of defensive stability, robust research pipelines, and reliable dividend income for long-term investors.
Amgen has faced multiple corporate and regulatory controversies over the years, spanning complex patent infringement lawsuits regarding biologic drug manufacturing, pricing scrutiny from government healthcare committees concerning high-cost therapeut...
Amgen has implemented targeted workforce reduction measures as part of ongoing post-acquisition integration efforts and strategic operational realignments designed to streamline research and development activities.
Amgen recently reported strong financial results for the second quarter, beating Wall Street earnings and revenue expectations while crossing the ten-billion-dollar quarterly revenue threshold for the first time.
Ozempic is not manufactured or commercialized by Amgen; it is developed, produced, and distributed globally by the Danish multinational pharmaceutical corporation Novo Nordisk.
Wall Street analyst consensus typically categorizes Amgen as a hold or moderate buy rather than an overwhelming strong buy.
Amgen Inc., traded under the ticker symbol AMGN, is classified as a large-cap biotechnology stock operating within the healthcare sector.
Amgen's product portfolio is anchored by several blockbuster medications, with Prolia and Xgeva (denosumab) for bone health and osteoporosis leading revenue generation, bringing in billions of dollars annually.
Assessing Amgen as a long-term equity investment involves analyzing secular growth trends in biopharmaceutical drug development, an extensive pipeline of innovative therapeutics, and a stellar history of dividend growth.